1. Aitken M, Kleinrock M, Muñoz E. Global medicine spending and usage trends: outlook to 2025. IQVIA. 2021. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicine-spending-and-usage-trends-outlook-to-2025. Accessed 7 Jan 2022.
2. Troein P, Newton M, Scott K, Mulligan C. The impact of biosimilar competition in Europe. IQVIA, White paper. 2021. https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021. Accessed 23 May 2022.
3. European Medicines Agency and European Commission. Biosimilars in the EU: information guide for healthcare professionals. 2019. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 24 Nov 2021.
4. Blackstone EA, Fuhr JP Jr. The economics of biosimilars. Am Health Drug Benefits. 2013;6:469–77.
5. Finnish Medicines Agency Fimea. Drug consumption in 2018–2021 [in Finnish]. 2022. http://raportit.nam.fi/raportit/kulutus/laakekulutus.pdf. Accessed 21 May 2022.